3 C
New York
Tuesday, January 31, 2023

It’s Not Over Yet For Ocugen Inc. (NASDAQ: OCGN)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Ocugen Inc. (OCGN) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.03, or 2.33%, to $1.32. The Ocugen Inc. has recorded 114,303 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

Ocugen Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $1.29 and fluctuated between $1.3000 as its day high and $1.2500 as its day low. The current market capitalization of Ocugen Inc. is $273.67M. A total of 3.94 million shares were traded on the day, compared to an average of 4.48M shares.

In the most recent transaction, Musunuri Shankar sold 95,809 shares of OCGN for 1.43 per share on Dec 16. After the transaction, the Chief Executive Officer now owns 752,540 company shares. In a previous transaction on Oct 14, Musunuri Shankar sold 100,000 shares at 1.66 per share. OCGN shares that Chief Executive Officer owns now total 752,540.

Among the insiders who sold shares, Kumar Ramesh disposed of 4,500 shares on Oct 06 at a per-share price of $1.83. This resulted in the Director holding 0 shares of OCGN after the transaction. In another insider transaction, Castillo Kirsten sold 42,000 shares at $2.91 per share on Aug 11. Company shares held by the Director now total 50,000.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for OCGN in the last 3 months, the mean price target is $5.33 with high estimates of $8.00 and low estimates of $3.50. In terms of 52-week highs and lows, OCGN has a high of $4.64 and a low of $1.09.

As of this writing, OCGN has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.12.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCGN is Overweight with a score of 4.67. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles